Q3 2017 13F Holders as of 9/30/2017
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
112M
-
Number of holders
-
16
-
Total 13F shares, excl. options
-
2.02M
-
Shares change
-
+568K
-
Total reported value, excl. options
-
$3.85M
-
Value change
-
+$1.49M
-
Number of buys
-
10
-
Number of sells
-
-3
-
Price
-
$1.91
Significant Holders of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) as of Q3 2017
18 filings reported holding VKTX - Viking Therapeutics, Inc. - COMMON STOCK as of Q3 2017.
Viking Therapeutics, Inc. - COMMON STOCK (VKTX) has 16 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.02M shares
of 112M outstanding shares and own 1.8% of the company stock.
Largest 10 shareholders include ASCEND CAPITAL, LLC (488K shares), RENAISSANCE TECHNOLOGIES LLC (403K shares), VANGUARD GROUP INC (339K shares), SPHERA FUNDS MANAGEMENT LTD. (290K shares), Park West Asset Management LLC (200K shares), SHEPHERD KAPLAN KROCHUK, LLC (75.6K shares), CITADEL ADVISORS LLC (56.5K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (51.2K shares), Virtu Financial LLC (36.6K shares), and GEODE CAPITAL MANAGEMENT, LLC (31.3K shares).
This table shows the top 16 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.